- Credit Suisse says that Ventyx Biosciences Inc's VTYX topline Phase 1 MAD data for its allosteric TYK2 inhibitor, VTX958 establishes clear differentiation from other TYK2is and meaningfully de-risk the drug's profile.
- Credit Suisse raised the price target to $63 from $53 with an Outperform rating.
- VTYX plans on initiating Phase 2 Proof of Concept trials in psoriasis, psoriatic arthritis, and Crohn's disease (CD) in Q4.
- VTX958 achieved dose-dependent exposure/target coverage, with up to 24 hours of TYK2 IC50/IC90 coverage and class-leading coverage of its target cytokines, writes the analyst.
- Early data suggests VTX958 can achieve better exposure/TYK2 pathway suppression with a wider safety margin.
- According to Credit Suisse, VTX958 is particularly well positioned for success in CD, a ~$12 billion indication without any oral therapies that likely require greater TYK2 coverage than psoriasis for adequate disease management.
- VTYX trades at ~$700 million EV and funds into H1 2024.
- The analysts see the company offers a compelling investment opportunity with a highly favorable upside/downside.
- Price Action: VTYX shares are up 32.20% at $24.61 during the last check on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
